常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.90/-0.59
|
|
企业价值
12.20M
|
| 资产负债 |
|
每股账面净值
0.97
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
501.00K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/15 11:11 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105. |

0.3744 
